Nkarta to Participate at Upcoming Investor Conferences
Nkarta, a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, will present at three key investor conferences: SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 1:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta, a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, will present at three key investor conferences:
- SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 1:40 p.m. ET.
- Cowen 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET.
- Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 10:00 a.m. ET.
Webcasts of these presentations will be available on the company's website, with replays archived for approximately four weeks.
Details
News Market Reaction – NKTX
The recorded move for NKTX in the trading session of this news was -3.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:
SVB Leerink 11th Annual Global Healthcare Conference
February 17, 2022
1:40 p.m. ET – fireside chat presentation
Cowen 42nd Annual Health Care Conference
March 7, 2022
10:30 a.m. ET – leukemias panel discussion
Oppenheimer 32nd Annual Healthcare Conference
March 16, 2022
10:00 a.m. ET – presentation
A simultaneous webcast of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.